Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
June 2017
-
Media Release
Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®
New 96-week data support durability and safety of Treatment-free Remission (TFR) in Ph+ CML-CP patients who stop taking Tasigna [1,2] More than 90% of Ph+ CML-CP patients in ENESTfreedom and ENESTop… -
Media Release
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data Data evaluating 63… -
Media Release
Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
Approval provides first targeted treatment in the US specifically for BRAF V600E mutation-positive metastatic NSCLC More than 60% of treatment-naïve and previously treated patients with… -
Featured News
Asthma and exercise: why patients can and should stay active
-
Media Release
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces… -
Media Release
Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance
AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance Filing is supported by a comprehensive clinical… -
Helping Syrian refugees manage chronic diseases
Among the many Syrians uprooted by armed conflict are thousands of people with chronic conditions – such as diabetes and heart disease - whose treatment was disrupted when they fled.
-
Media Release
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
RTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48[1],[2] in two head-to-head pivotal Phase III studies[3],[4]… -
Media Release
Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden
Urgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by… -
Media Release
Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases
European Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare… -
Media Release
Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease
Large-scale European patient survey found that 94% of severe allergic asthma patients were unable to fully control their disease These new data underscore the disconnect between self-… -
Media Release
FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®
FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus® Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference…
Pagination
- ‹ Previous page
- 1
- …
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- …
- 154
- › Next page
Test disclaimer...!!!